BC
APLS

Boxer Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Boxer Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,726,000
Closed -$49.8M – 4
2024
Q3 		$49.8M Hold
1,726,000
– – 2.44% 13
2024
Q2 		$66.2M Hold
1,726,000
– – 3.49% 12
2024
Q1 		$101M Hold
1,726,000
– – 5.01% 5
2023
Q4 		$103M Hold
1,726,000
– – 5.15% 5
2023
Q3 		$65.7M Buy
1,726,000
+150,000
+10% +$6.59M 3.5% 9
2023
Q2 		$144M Hold
1,576,000
– – 6.66% 2
2023
Q1 		$104M Hold
1,576,000
– – 5.11% 5
2022
Q4 		$81.5M Buy
1,576,000
+272,300
+21% +$14.4M 4.3% 7
2022
Q3 		$89M Hold
1,303,700
– – 5.01% 5
2022
Q2 		$59M Hold
1,303,700
– – 3.73% 5
2022
Q1 		$66.2M Buy
+1,303,700
New +$57.6M 3.4% 10
2020
Q1 		– Sell
-800,000
Closed -$24.5M – 63
2019
Q4 		$24.5M Buy
800,000
+100,000
+14% +$2.77M 1.39% 20
2019
Q3 		$16.9M Buy
+700,000
New +$19.3M 1.22% 24

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Boxer Capital's APLS Position: Q4 2024 in Review

Boxer Capital sold out of Apellis Pharmaceuticals (APLS) in Q4 2024, closing a stake of 1,726,000 shares — an estimated $49.8M sold.

Boxer Capital first reported a position in APLS in Q3 2019 and held it in 13 quarters. The position peaked at $144M in Q2 2023. 260 funds tracked by Wall St. Rank hold APLS as of Q4 2024.

  • Boxer Capital reported no remaining Apellis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Boxer Capital sold 1,726,000 Apellis Pharmaceuticals shares in Q4 2024, an estimated $49.8M.
  • Boxer Capital first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 13 quarters.
  • Boxer Capital's Apellis Pharmaceuticals position peaked at $144M in Q2 2023.
  • 260 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.